Payment overview · 2025
General Payments
$266.31
14 reported records · 7 companies
Healthcare provider profile · identity verified
Larry J Marshall, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LAKESIDE, CA · NPI 1114018132
Verified facts
What the public records show
CMS Open Payments records show Larry J Marshall, MD received $266.31 in general payments during 2025 across 14 reported records.
Lilly USA, LLC accounted for 36.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $96.71 | 36.3% | 4 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $52.53 | 19.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $52.27 | 19.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $18.19 | 6.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $16.68 | 6.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.39 | 6.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.54 | 5.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $266.31 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.76 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.76 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $46.95 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $34.66 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Normalized: watchman |
Device | Boston Scientific Corporation | $19.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $17.61 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $17.10 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $16.68 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.39 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 38 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
38 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 467 | 129 |
| Hydrochlorothiazide | Hydrochlorothiazide | 320 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 289 | 72 |
| Lisinopril | Lisinopril | 265 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 251 | 77 |
| Metformin Hcl | Metformin Hcl | 239 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 215 | 62 |
| Gabapentin | Gabapentin | 188 | 60 |
| Meloxicam | Meloxicam | 185 | 64 |
| Losartan Potassium | Losartan Potassium | 152 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 129 | 37 |
| Carvedilol | Carvedilol | 124 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 32 |
| Alprazolam | Alprazolam | 120 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 39 |
| Trazodone Hcl | Trazodone Hcl | 108 | 34 |
| Celecoxib | Celecoxib | 103 | 35 |
| Simvastatin | Simvastatin | 102 | 24 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 100 | 22 |
| Furosemide | Furosemide | 99 | 33 |
| Potassium Chloride | Potassium Chloride | 96 | 30 |
| Tramadol Hcl | Tramadol Hcl | 86 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 82 | 22 |
| Omeprazole | Omeprazole | 74 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 73 | 31 |
| Atenolol | Atenolol | 67 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 67 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 24 |
| Azithromycin | Azithromycin | 56 | 46 |
| Meclizine Hcl | Meclizine Hcl | 55 | 21 |
| Glipizide | Glipizide | 54 | 15 |
| Naproxen | Naproxen | 53 | 30 |
| Alendronate Sodium | Alendronate Sodium | 51 | suppressed |
| Methocarbamol | Methocarbamol | 50 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 46 | 26 |
| Lovastatin | Lovastatin | 45 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 44 | suppressed |
| Methylprednisolone | Methylprednisolone | 44 | 37 |
| Montelukast Sodium | Montelukast Sodium | 44 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 44 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 40 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 27 |
| Eliquis | Apixaban | 38 | 14 |
| Pregabalin | Pregabalin | 38 | 11 |
| Sertraline Hcl | Sertraline Hcl | 38 | 12 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Finasteride | Finasteride | 35 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 28 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 24 | suppressed |
| Topiramate | Topiramate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 18 |
| Ozempic | Semaglutide | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Ssd | Silver Sulfadiazine | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Cephalexin | Cephalexin | 15 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levocarnitine | Levocarnitine | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Olanzapine | Olanzapine | 15 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Amantadine | Amantadine Hcl | 14 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ezetimibe | Ezetimibe | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $266.31 · 14 records | Lilly USA, LLC | AREXVY, ELIQUIS, General - Pain Management, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, WATCHMAN, WaveWriter Alpha Prime 16, ZAVZPRET, ZEPBOUND, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error